(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)
* British shops and pub gardens reopen as lockdown eases
* C4X Discovery ends at 18-month high on deal with Sanofi
* AstraZeneca falls after diabetes drug fails to meet main goal
* FTSE 100, FTSE 250 drop 0.4%
(Updates to close)
By Devik Jain and Shashank Nayar
April 12 (Reuters) - London's FTSE 100 ended lower on Monday, as heavyweight mining stocks slipped amid a drop in metal prices and a stronger pound weighed on the export-heavy index, while shares of drug developer C4X Discovery surged after a licensing deal with Sanofi.
The blue-chip index .FTSE ended 0.4% lower after recording its best weekly performance since early January on Friday.
The domestically focussed mid-cap FTSE 250 index .FTMC dropped 0.4% even as England's shops, pubs, gyms and hairdressers reopened after three months of strict winter lockdown. is not much cheer on the reopening as it seems to be already factored in and neither are concerns of cases increasing as shops reopen," said Keith Temperton, equity sales trader at Forte Securities.
"Investors seems to be holding back as markets have rallied in a short time, and would wait until the earnings season kicks in.”
The FTSE 100 has risen 6.6% since the beginning of the year as huge vaccine rollouts coupled with added government stimulus helped boost investor optimism about a faster economic rebound. But a recent drop in metal prices and elevated yield levels have kept gains limited.
C4X Discovery C4XD.L jumped nearly 8% after the drug developer signed an exclusive licensing deal worth up to $492.12 million with French drugmaker Sanofi SASY.PA to develop an oral therapy for treatment of inflammatory diseases. HMSO.L dropped 2.9% after it confirmed that it was in talks for a possible sale of its retail parks portfolio to Canadian private equity player Brookfield Asset Management BAMa.TO . AZN.L fell 0.9% and was the third biggest drag on the FTSE 100 as data from a late-stage study to test whether its diabetes drug Farxiga could treat patients hospitalised with COVID-19 and at risk of developing serious complications fell short of its main goals.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.